-+ 0.00%
-+ 0.00%
-+ 0.00%

Acumen Q1 FY26 net loss narrows to $20.7 million; R&D expenses fall to $16.5 million

PUBT·05/12/2026 11:07:34
Listen to the news
Acumen Q1 FY26 net loss narrows to $20.7 million; R&D expenses fall to $16.5 million
  • Acumen Pharmaceuticals posted a Q1 net loss of USD 20.7 million, narrowing from USD 28.8 million a year earlier, as operating loss improved to USD 21.1 million from USD 30.4 million.
  • R&D expense fell to USD 16.5 million from USD 25.3 million on lower manufacturing and materials costs, plus reduced CRO spending tied to the ALTITUDE-AD trial after enrollment completed in March 2025.
  • Cash, cash equivalents and marketable securities rose to USD 128.4 million as of March 31, 2026, up from USD 116.9 million at year-end 2025, following a March private placement that generated USD 35.75 million in gross proceeds.
  • Topline results from the ALTITUDE-AD Phase 2 study of sabirnetug (ACU193) in early Alzheimer’s disease are expected in late 2026, with an IND filing for a lead candidate in its EBD program targeted for mid-2027.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Acumen Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605120700PRIMZONEFULLFEED9717849) on May 12, 2026, and is solely responsible for the information contained therein.